GeoVax (United States)

GeoVax (United States)

GeoVax is a clinical-stage biotechnology company which develops vaccines. GeoVax's development platform uses Modified Vaccinia Ankara vector technology, with improvements to antigen design and manufacturing capabilities. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for GeoVax (United States), United States, covering academic research published from 2007 to 2024. Read More.


Open Access Percentage

78%


Total
Publications

54


Total Open
Publications

42


Total
Citations

1.2K


Open Access
Percentage

78%


Total
Publications

54


Total Open
Publications

42


Total
Citations

1.2K

Wikipedia

Website

download

Breakdown

10% 59% 9% 22%

Publisher Open

10%

Both

59%

Other Platform Open

9%

Closed

22%

Percentage of Open Access over time

0%10%20%30%40%50%60%70%80%90%100%
200720082009201020112012201320142015201620172018201920202021202220232024

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

012345678Total Publications
200720082009201020112012201320142015201620172018201920202021202220232024

Open

Closed

Publisher Open

51%OA Journal

OA Journal 51%

19

Hybrid 11%

4

No Guarantees 38%

14

Other Platform Open

Domain 100%

37

Public 16%

6

Institution 8%

3

Preprint 0%

0

Other Internet 0%

0

Other Platform Locations

Name

Platform Type

Publications

PubMed Central
Domain
37
Europe PMC
Domain
27
Semantic Scholar
Public
6
University of Massachusetts Medical School - eScholarship@UMMS
Institution
2
University of North Carolina at Chapel Hill - Carolina Digital Repository
Institution
1
Harvard University - Digital Access to Scholarship at Harvard (DASH)
Institution
1
Figshare
Public
1
1 / 1

Data updated 13 February 2025

Share

Share

Share